Bulk Pharmaceutical API Sources for PRIALT

Bulk Pharmaceutical API Sources for PRIALT

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS015994641
Molport		MolPort-009-194-186
Key Organics/BIONET		HS-2032
BOC Sciences		107452-89-1
Glentham Life Sciences Ltd.		GK7741
Sigma-Aldrich		C1182_SIGMA

PRIALT Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk Active Pharmaceutical Ingredient (API) sourcing for PRIALT (ziconotide). PRIALT is a synthetic conopeptide, a neurotransmitter blocker, used for severe chronic pain management. The global API market for PRIALT is characterized by a limited number of specialized manufacturers and stringent regulatory requirements. Sourcing decisions are driven by API quality, regulatory compliance, supply chain reliability, and cost.

What is the Current Status of PRIALT API Manufacturing?

The manufacturing of ziconotide API is a complex process due to its peptide nature and required high purity. It involves solid-phase or solution-phase peptide synthesis followed by purification and lyophilization. The synthetic route is proprietary to the innovator company, and its complexity limits the number of potential manufacturers.

• Innovator Control: Eisai Co., Ltd. is the primary innovator and marketer of PRIALT (brand name Prialt). Their manufacturing and sourcing strategies are central to the API landscape.
• Limited Third-Party Manufacturers: Due to the proprietary nature of the synthesis and the stringent quality controls required for a neuro-active peptide, the number of third-party API manufacturers capable of producing ziconotide at commercial scale is exceptionally small. These manufacturers often operate under strict licensing agreements or as contract manufacturing organizations (CMOs) for Eisai.
• Regulatory Hurdles: The production of ziconotide API requires adherence to current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes comprehensive analytical testing, impurity profiling, and stability studies.

What are the Key Sourcing Considerations for PRIALT API?

Sourcing PRIALT API involves evaluating several critical factors to ensure supply continuity, product quality, and regulatory compliance.

• Quality and Purity: Ziconotide is a potent neuroactive peptide. API purity is paramount to ensure therapeutic efficacy and patient safety. Specifications typically include:
  • Assay: ≥ 98.0%
  • Related Substances (impurities): Individual unspecified impurities ≤ 0.10%, Total impurities ≤ 1.0%
  • Water Content: ≤ 5.0%
  • Residual Solvents: Must comply with ICH Q3C guidelines.
  • Endotoxins: Specific limits for parenteral administration.
• Regulatory Compliance: API manufacturers must possess a Drug Master File (DMF) or equivalent regulatory submission with relevant health authorities. For the U.S., an FDA DMF is crucial. For Europe, a Certificate of Suitability to the European Pharmacopoeia (CEP) is often required.
  • DMF Status: Active DMFs are essential for seamless integration into drug product applications.
  • Inspection Readiness: Manufacturers must be prepared for routine cGMP inspections by regulatory agencies.
• Supply Chain Reliability: Given the limited number of manufacturers, supply chain resilience is a major concern. This includes:
  • Manufacturing Capacity: Ability to meet projected demand.
  • Geographic Diversification: While limited, sourcing from multiple qualified sites, if possible, can mitigate risk.
  • Lead Times: Production and delivery timelines for complex peptide APIs can be substantial.
• Cost and Commercial Terms: While quality and regulatory compliance are non-negotiable, the cost of goods is a significant factor in the overall profitability of the finished drug product.
  • Pricing Structure: Typically negotiated based on volume, contract duration, and specific quality agreements.
  • Payment Terms: Standard industry terms apply.

Who are the Potential Bulk API Suppliers for PRIALT?

The market for PRIALT bulk API is concentrated. Direct sourcing from Eisai or its designated CMOs represents the primary pathway. Identifying independent, non-affiliated suppliers who have developed their own synthetic routes and secured regulatory approval is challenging due to intellectual property and the high barrier to entry.

• Innovator Company:
  • Eisai Co., Ltd.: As the innovator and registered holder of the PRIALT marketing authorization, Eisai is the primary source for ziconotide API. They either manufacture it internally or through exclusive contract manufacturing agreements. Their internal manufacturing sites or those of their exclusive partners hold the primary regulatory filings.
• Potential Contract Manufacturing Organizations (CMOs) / Contract Development and Manufacturing Organizations (CDMOs):
  • While specific details are often confidential, companies with extensive experience in complex peptide synthesis and cGMP manufacturing for injectables are theoretically capable. These would likely be highly specialized firms, often operating under exclusive agreements with the innovator. Examples of companies with relevant expertise in peptide API manufacturing include (but are not limited to, and without specific confirmation of PRIALT production):
    • Bachem AG: A leading peptide manufacturer with significant cGMP capacity and regulatory experience.
    • Lonza: Offers broad CDMO services, including complex API synthesis.
    • Carbogen Amcis AG: Specializes in complex APIs, including peptides.
    • AbbVie (formerly Allergan): While known for finished drug products, some pharmaceutical companies have internal API manufacturing capabilities that could potentially be leveraged through agreements.
• Generic API Manufacturers:
  • The development of generic ziconotide is significantly hampered by the complexity of its synthesis and the need to establish bioequivalence and comparable impurity profiles to the reference listed drug (RLD). The patent landscape for ziconotide itself and its manufacturing processes would need to be carefully reviewed for any patent expiry dates that might enable generic competition. As of the latest available information, a robust generic API supply market for ziconotide has not emerged, indicating significant technical and regulatory barriers or ongoing patent protection.

What is the Regulatory Landscape for Ziconotide API?

The regulatory framework governing ziconotide API is rigorous, emphasizing patient safety and product consistency.

• U.S. Food and Drug Administration (FDA):
  • cGMP Compliance: All API manufacturing facilities must comply with 21 CFR Part 210 and 211.
  • Drug Master File (DMF): Manufacturers typically file Type II DMFs, which contain detailed information about the facility, manufacturing process, quality control, and stability of the API. This allows drug product manufacturers to reference the DMF in their Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) without disclosing proprietary information to the drug product applicant.
  • Facility Inspections: The FDA conducts pre-approval inspections (PAIs) and routine surveillance inspections of API manufacturing sites.
• European Medicines Agency (EMA):
  • EudraGMP Database: Manufacturers must be registered and compliant with EudraGMP.
  • Certificate of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP demonstrates that the API complies with the requirements of the relevant European Pharmacopoeia monograph. This simplifies the regulatory process for Marketing Authorisation Applications (MAAs) in Europe.
  • Qualified Person (QP) Declaration: For APIs imported into the EU, a QP must certify that each batch has been manufactured in accordance with GMP.
• International Council for Harmonisation (ICH) Guidelines:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q3A/B/C/D: Impurities in New Drug Substances, Drug Products, Residual Solvents, and Elemental Impurities.
  • ICH Q1A-F: Stability testing guidelines.

What is the Intellectual Property (IP) Landscape Affecting PRIALT API?

The patent landscape for ziconotide and its manufacturing processes is crucial for understanding market entry for potential new API suppliers.

• Composition of Matter Patents: The original patents covering the ziconotide molecule itself are likely expired or nearing expiry. However, the innovator may hold secondary patents related to specific salt forms, polymorphs, or formulations.
• Process Patents: Patents covering the specific synthetic routes, purification methods, and scale-up processes are significant barriers. These patents are often held by the innovator and protect their manufacturing advantage.
• Exclusivity Periods: Regulatory exclusivities granted to the innovator (e.g., New Chemical Entity (NCE) exclusivity, Orphan Drug exclusivity) can also extend market protection beyond patent expiry.
• Patent Monitoring: Thorough patent landscape analysis is essential for any company considering entering the ziconotide API market, particularly for generic manufacturers. This includes identifying:
  • Patents on the ziconotide molecule.
  • Patents on manufacturing processes.
  • Patents on specific intermediates or reagents used in synthesis.
  • Patents on pharmaceutical compositions or delivery systems.

What are the Future Trends and Challenges in PRIALT API Sourcing?

The PRIALT API market faces ongoing challenges and potential future shifts.

• Continued Reliance on Innovator Supply Chain: Due to the technical and regulatory complexity, the market is likely to remain dominated by the innovator or its designated partners for the foreseeable future.
• Emergence of Biosimilars/Generics: While challenging, if patent protections expire and manufacturing hurdles are overcome, generic ziconotide APIs could eventually emerge. This would require significant investment in process development, analytical characterization, and regulatory submissions.
• Supply Chain Security and Resilience: Global events have highlighted the importance of secure and resilient supply chains. Pharmaceutical companies will continue to prioritize suppliers with robust business continuity plans and diversified manufacturing operations where feasible.
• Advancements in Peptide Synthesis: Innovations in peptide synthesis technologies, such as continuous flow chemistry or enzymatic synthesis, could potentially lower manufacturing costs and improve efficiency, although their application to complex peptides like ziconotide requires substantial validation.
• Sustainability in Manufacturing: Increasing regulatory and corporate focus on environmental sustainability may influence manufacturing site selection and process development, favoring greener chemistry and waste reduction.

Key Takeaways

• The PRIALT API market is highly concentrated, with Eisai Co., Ltd. and its designated CMOs being the primary and often sole commercial sources.
• Sourcing decisions are driven by stringent quality requirements, cGMP compliance, robust regulatory filings (DMFs, CEPs), and supply chain reliability.
• The complex peptide synthesis and proprietary manufacturing processes create significant barriers to entry for third-party API manufacturers.
• Intellectual property, particularly process patents, plays a critical role in shaping market access and potential generic competition.
• Regulatory hurdles are substantial, requiring adherence to global cGMP standards and successful navigation of FDA and EMA approval processes.

Frequently Asked Questions

1. Are there publicly listed independent manufacturers of ziconotide API? Publicly available information does not identify independent, non-affiliated manufacturers actively supplying ziconotide API at commercial scale. The market is primarily controlled by the innovator, Eisai, and their contracted manufacturing partners.

2. What is the typical lead time for sourcing bulk PRIALT API? Lead times for complex peptide APIs like ziconotide are generally longer than for small molecule drugs, often ranging from 6 to 12 months or more, depending on existing manufacturing schedules, batch size, and specific quality requirements.

3. Can a company develop a generic version of PRIALT API without licensing from Eisai? Developing a generic version is technically possible upon patent expiry but requires independent development of a non-infringing synthetic process, extensive analytical characterization, demonstration of equivalence to the reference drug, and successful navigation of regulatory approval processes, which are highly complex for peptide APIs.

4. What are the main regulatory challenges for a new ziconotide API manufacturer? The main challenges include demonstrating robust cGMP compliance for peptide synthesis, developing and validating a comprehensive analytical testing program to control impurities, establishing a complete and approvable Drug Master File (DMF), and successfully passing facility inspections by regulatory authorities like the FDA and EMA.

5. Does the cost of ziconotide API fluctuate significantly? For existing supply agreements, pricing is typically negotiated and fixed for a period. However, for new entrants or in the context of potential generic competition, pricing would be subject to significant negotiation, manufacturing cost efficiencies, and market demand dynamics, which can lead to fluctuations.

Citations

[1] Eisai Co., Ltd. (n.d.). Prialt (ziconotide) Product Information. Retrieved from manufacturer's official website. (Note: Specific product information URLs can change; this is a representative citation.) [2] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry [3] European Medicines Agency. (n.d.). Manufacturing and Quality. Retrieved from https://www.ema.europa.eu/en/human-regulatory/manufacturing-quality [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/guidelines [5] Patent databases (e.g., USPTO, EPO, WIPO). (n.d.). Searches for ziconotide and related manufacturing processes. (Note: Specific patent numbers and search parameters are beyond the scope of this general report but would be crucial for detailed IP analysis.)